Insulin resistance in type 1 diabetes is real, increasingly common, and treatable through a combination of lifestyle changes and, in some cases, medications added alongside insulin. Sometimes called “double diabetes,” this occurs when someone whose body already can’t produce insulin also becomes less responsive to the insulin they inject. The result: rising doses, more erratic blood sugar, weight gain, and higher cardiovascular risk. Addressing it requires a different playbook than standard type 1 management.
Why Insulin Resistance Develops in Type 1
Type 1 diabetes is an autoimmune condition that destroys insulin-producing cells. Insulin resistance is a separate problem, one traditionally associated with type 2 diabetes, where the body’s cells stop responding efficiently to insulin. When both occur in the same person, the term “double diabetes” applies. It was first described in 1991, when researchers noticed that people with type 1 diabetes who had a family history of type 2 were more likely to be overweight and rarely achieved good blood sugar control, even on higher insulin doses.
The logic is straightforward: some people carry genetic susceptibility to both conditions. Had their immune system not destroyed their beta cells first, they might have eventually developed type 2 diabetes on its own. But because type 1 came first, the insulin resistance layers on top of complete insulin dependence, creating a uniquely difficult management challenge. Excess fat tissue, particularly around the midsection and heart, also plays a direct role by releasing inflammatory signals that blunt insulin’s effectiveness.
How to Spot It
Insulin resistance in type 1 doesn’t show up on a single lab test. Instead, it reveals itself through patterns. The most telling sign is a steadily climbing total daily insulin dose without a corresponding change in diet or activity. If you’re injecting significantly more insulin than you used to and your blood sugars are still running high, resistance is a likely culprit.
Clinicians use a calculation called the estimated glucose disposal rate (eGDR) that factors in waist circumference, blood pressure, and HbA1c to estimate how insulin-resistant a person with type 1 is. Lower scores indicate more resistance. People in the most insulin-resistant group (eGDR below about 5.4) consistently show worse outcomes.
If you use a continuous glucose monitor, your data tells a story too. Research comparing CGM profiles to insulin resistance scores found that people with more resistance spent significantly more time above range (39% versus 33% for the most insulin-sensitive group) and had lower time in range overall. Persistently elevated time above range despite aggressive dosing is a practical red flag you can track yourself.
Exercise: The Most Effective Tool
Physical activity is the single most powerful way to improve insulin sensitivity, and resistance training (weightlifting, bodyweight exercises, resistance bands) has specific advantages for people with type 1 diabetes. When muscles contract during exercise, they pull glucose out of the blood through a mechanism that works independently of insulin. This insulin-like effect persists: after a strength training session, your muscles remain more sensitive to insulin for up to 48 hours.
Resistance training also causes less of the acute blood sugar drops that make aerobic exercise tricky for people on insulin. While running or cycling can cause rapid glucose declines during the activity itself, lifting weights produces a more gradual effect and is associated with longer-lasting reductions in post-exercise blood sugar. Over time, the increase in muscle mass creates more tissue that actively absorbs glucose, reducing the total amount of insulin you need.
Clinical trials in type 1 diabetes have tested programs lasting 12 to 32 weeks, typically involving three sessions per week. Effective protocols ranged from circuit-style workouts of 20 to 40 minutes to more traditional formats of 3 sets of 8 to 12 repetitions across 7 or 8 exercises. The common thread was consistency over months, not any single “best” routine. Starting at moderate intensity (around 50 to 60% of your maximum) and building gradually is a reasonable approach.
Dietary Changes That Reduce Insulin Needs
Reducing carbohydrate intake lowers the amount of insulin you need at meals, which can break a cycle where high insulin doses themselves contribute to resistance. In one intervention study, people with type 1 diabetes who followed a carbohydrate-restricted diet dropped their daily insulin use from an average of 64 units to 44 units per day. Their HbA1c improved from 7.9% to 7.2% over the same period.
The mechanism is partly straightforward (fewer carbs means less mealtime insulin) and partly indirect. Chronically high insulin exposure may itself worsen resistance, based on animal and observational data. By reducing the total insulin load, lower-carb eating may help restore some sensitivity. You don’t need to go extremely low-carb to see benefits. Even a moderate reduction, swapping refined grains for vegetables, legumes, and healthy fats, can meaningfully lower your daily dose and smooth out glucose swings.
Metformin as an Add-On
Metformin, the cornerstone drug for type 2 diabetes, works by reducing the amount of glucose the liver releases and by improving how cells respond to insulin. Adding it to a type 1 regimen has been studied for decades. In clinical research, metformin reduced insulin requirements by about 26% while actually lowering average blood glucose levels. That’s a meaningful reduction in how much insulin someone needs to inject each day.
Metformin won’t replace insulin in type 1 diabetes. You still need it. But by cutting the total dose, it can help with the weight gain and metabolic effects that come from taking large amounts of exogenous insulin. It’s inexpensive, widely available, and generally well tolerated, though gastrointestinal side effects (nausea, bloating, diarrhea) are common when starting and typically improve over a few weeks.
GLP-1 Medications: A Newer Option
GLP-1 receptor agonists, the drug class that includes liraglutide, semaglutide, and dulaglutide, have shown consistent benefits when added to insulin therapy in type 1 diabetes. Across multiple clinical trials, these medications produced roughly 5% body weight loss compared to placebo and reduced total daily insulin doses by 5 to 17%, depending on the specific drug and dose. A meta-analysis estimated that liraglutide at its higher dose led to approximately 5 kilograms (about 11 pounds) of weight loss compared to placebo.
One small but striking study with semaglutide found that all 10 participants were able to stop mealtime insulin entirely, and 7 of 10 also stopped basal insulin, though these patients likely had some remaining insulin production. Larger, controlled trials showed more modest but still meaningful results: insulin dose reductions of 7 to 15% alongside improved HbA1c of 0.2 to 0.7 percentage points.
These medications are not yet approved specifically for type 1 diabetes, so their use is off-label. But the evidence base is growing, and for people with type 1 who also carry significant excess weight and insulin resistance, they address multiple problems simultaneously: reducing appetite, promoting weight loss, lowering insulin requirements, and modestly improving blood sugar control.
Tirzepatide: Early Results
Tirzepatide, a newer medication that targets two gut hormone receptors instead of one, was recently tested in a phase 2 trial in adults with type 1 diabetes and a BMI over 30. Over 12 weeks, participants on tirzepatide reduced their total daily insulin dose by 35% compared to placebo and saw HbA1c improve by 0.4 percentage points. The drug was also superior to placebo for weight loss. These are early results from a small trial, but the magnitude of the insulin dose reduction is notable.
SGLT2 Inhibitors: Benefits With a Serious Caveat
SGLT2 inhibitors, which work by causing the kidneys to excrete excess glucose in urine, have shown improvements in blood sugar control and weight loss in type 1 diabetes. However, they carry a significant and dose-dependent risk of diabetic ketoacidosis (DKA), a dangerous buildup of acid in the blood. What makes this particularly tricky is that the DKA can occur at relatively normal blood sugar levels, meaning the usual warning sign of very high glucose may be absent.
International consensus guidelines recommend starting at the lowest possible dose if these medications are used in type 1 diabetes, with some clinicians even splitting tablets to achieve doses lower than what’s commercially available. In clinical trials, a very low dose of one SGLT2 inhibitor (2.5 mg of empagliflozin) had a ketoacidosis rate comparable to placebo, while higher doses showed increased risk. If you take one of these medications, knowing the symptoms of DKA (nausea, vomiting, abdominal pain, rapid breathing, unusual fatigue) and informing any emergency medical team that you’re on an SGLT inhibitor is essential.
Putting It Together
Treating insulin resistance in type 1 diabetes works best as a layered approach. Exercise and dietary changes form the foundation and carry no medication risks. Resistance training three times per week, combined with even moderate carbohydrate reduction, can meaningfully lower insulin requirements and improve glucose patterns within a few months. Adding metformin is a low-cost next step with decades of safety data. GLP-1 medications offer additional weight loss and insulin reduction for those who need more, particularly people carrying significant excess weight. Each layer compounds the effects of the others.
Tracking progress is practical with tools you likely already have. Your total daily insulin dose is the simplest metric: a sustained downward trend with stable or improving blood sugars means your sensitivity is improving. If you wear a CGM, watch your time in range and time above range. Waist circumference, measured at home with a tape measure, captures the visceral fat changes that most directly drive resistance. These numbers, tracked monthly, give you a clear picture of whether your approach is working.